Denali Therapeutics Company
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Investors
Last Funding Type:
Series B
Last Funding Date:
2016
Funding Status:
IPO
Headquarters:
UK
Industry:
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Estimated Revenue:
$10M to $50M
Total Funding:
347000000
Investors Number:
8
Employee Number:
251-500
Founded Date:
2015